Fate Therapeutics (FATE) Net Equity Issued and Repurchased (2012 - 2021)

Fate Therapeutics' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at -$31000.0 for Q4 2021.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$31000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$301000.0 (down 100.61% YoY) and the FY2021 annual result came in at $411.7 million, up 118.1% from the prior year.
• Net Equity Issued and Repurchased was -$31000.0 for Q4 2021 at Fate Therapeutics, up from -$270000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $173.1 million in Q3 2019 and bottomed at -$270000.0 in Q3 2020.
• A 5-year average of $51.5 million and a median of $23.0 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2018 — Net Equity Issued and Repurchased sank 100.53% — and 2019, when it surged 44.49%.
• Fate Therapeutics' Net Equity Issued and Repurchased stood at $46.0 million in 2017, then sank by 100.53% to -$245000.0 in 2018, then jumped by 44.49% to -$136000.0 in 2019, then sank by 98.53% to -$270000.0 in 2020, then jumped by 88.52% to -$31000.0 in 2021.
• Business Quant data shows FATE's Net Equity Issued and Repurchased at -$31000.0 in Q4 2021, -$270000.0 in Q3 2020, and $50.0 million in Q2 2020.